Last updated on December 2019

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Brief description of study

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex), once a week intramuscularly in participants with RMS.

Clinical Study Identifier: NCT04032158

Find a site near you

Start Over